UK markets close in 1 hour 35 minutes
  • FTSE 100

    7,743.84
    -41.03 (-0.53%)
     
  • FTSE 250

    19,807.08
    -130.12 (-0.65%)
     
  • AIM

    865.53
    -3.63 (-0.42%)
     
  • GBP/EUR

    1.1354
    -0.0025 (-0.22%)
     
  • GBP/USD

    1.2316
    -0.0038 (-0.31%)
     
  • BTC-GBP

    18,800.95
    -153.52 (-0.81%)
     
  • CMC Crypto 200

    524.95
    +6.15 (+1.19%)
     
  • S&P 500

    4,030.57
    +12.80 (+0.32%)
     
  • DOW

    33,730.99
    +13.90 (+0.04%)
     
  • CRUDE OIL

    77.66
    -0.24 (-0.31%)
     
  • GOLD FUTURES

    1,938.00
    -1.20 (-0.06%)
     
  • NIKKEI 225

    27,327.11
    -106.29 (-0.39%)
     
  • HANG SENG

    21,842.33
    -227.40 (-1.03%)
     
  • DAX

    15,075.04
    -51.04 (-0.34%)
     
  • CAC 40

    7,062.87
    -19.14 (-0.27%)
     

Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

ReportLinker
ReportLinker

In-depth Analysis of Top 50 Pharma CMOs: Capabilities, Results, Competition and Sales Potentials. The Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics.

New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022" - https://www.reportlinker.com/p06368576/?utm_source=GNW
It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The pharmaceutical industry is going through significant changes that are altering its business models, according to our analyst. This represents one of the new opportunities for market participants in the global pharmaceutical contract manufacturing organisations. According to our analysis, the pharmaceutical contract manufacturing organisations (CMOs) market is estimated to be valued at US$1,04,396 million in 2022 and is projected to reach a market value of US$2,03,240 million by 2032.

Growing Demand and Acceptability of Biosimilars Can Be Seen as a Big Opportunity for Pharma CMOs

Growing demand and acceptability of biosimilars can be seen as a big opportunity for contract manufacturing and research organisations. The requirement of affordable healthcare and upcoming patent expiries of innovative biologic drugs offers significant opportunities for biosimilars. Large pharma and biopharma companies see a huge opportunity in biosimilars. Rather than jump into the market on their own, most are interested in sharing their risks and working with collaborators. They are forming joint ventures or partnerships with the outsourcing providers. For Instance, in March 2022, Johnson and Johnson completed a historic agreement between Janssen Pharmaceuticals, Inc. and South African manufacturer Aspen SA Operations (Pty) Ltd to enable the first COVID-19 vaccine to be manufactured and made available by an African company for people living in Africa, with the goal of increasing COVID-19 vaccination rates across the continent.

What Questions Should You Ask before Buying a Market Research Report?

• How is the pharmaceutical contract manufacturing organisations (CMOs) market evolving?

• What is driving and restraining the pharmaceutical contract manufacturing organisations (CMOs) market?

• How will each pharmaceutical contract manufacturing organisations (CMOs) submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?

• What will be the main driver for the overall market from 2022 to 2032?

• Will leading pharmaceutical contract manufacturing organisations (CMOs) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

• Who are the leading players and what are their prospects over the forecast period?

• What are the pharmaceutical contract manufacturing organisations (CMOs) projects for these leading companies?

• How will the industry evolve during the period between 2022 and 2032? What are the implications of pharmaceutical contract manufacturing organisations (CMOs) projects taking place now and over the next 10 years?

• Is there a greater need for product commercialisation to further scale the pharmaceutical contract manufacturing organisations (CMOs) market?

• Where is the pharmaceutical contract manufacturing organisations (CMOs) market heading and how can you ensure you are at the forefront of the market?

• What are the best investment options for new product and service lines?

• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the pharmaceutical contract manufacturing organisations (CMOs) market today, and over the next 10 years:

• Our 370-page report provides 159 tables, 212 charts/graphs exclusively to you.

• The report highlights key lucrative areas in the industry so you can target them – NOW.

• It contains in-depth analysis of global, regional growth analysis.

• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the top 50 pharmaceutical contract manufacturing organisations (CMOs) market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.

• You will find original analyses, with business outlooks and developments.

• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), PEST Analysis, Porter’s Five Forces Analysis

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regions

• North America

• Europe

• Asia Pacific

• South America

• Middle East and Africa

The report also includes profiles and for some of the leading companies in the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

• Abbott Laboratories

• AbbVie Inc.

• Alkermes

• AstraZeneca

• Aurobindo Pharma

• Avid Bioservices, Inc.

• Bavarian Nordic

• Baxter Biopharma Solutions

• Bayer AG

• BD

• bioMérieux

• Boston Scientific Corporation

• CordenPharma International

• Catalent Inc.

• Consort Medical plc

• CSL Limited

• Divi’s Laboratories Ltd.

• Dr. Reddy’s Laboratories Ltd.

• Dupont

• Edwards Lifesciences Corporation

• Eli Lilly and Company

• Emergent BioSolutions

• Evonik Industries

• F. Hoffmann-La Roche Ltd.

• Fresenius SEandCo. KGaA

• Gilead Sciences, Inc.

• GSK plc

• Grifols

• Huapont Life Sciences Co Ltd.

• INOVIO Pharmaceuticals

• Johnson and Johnson Services Inc.

• Koninklijke DSM N.V. (Royal DSM)

• Lonza

• McKesson Corporation

• Merck KGaA

• Moderna Inc.

• Nipro Corporation

• Novartis AG

• Novavax

• Novo Nordisk A/S

• Pfizer Inc.

• PPD Inc.

• Sanofi

• Strides Pharma Science Limited

• Teva Pharmaceuticals Industries Ltd.

• Thermo Fisher Scientific Inc.

• UPM Pharmaceuticals

• VBI Vaccines Inc.

• WuXi AppTec

• ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.

Overall world revenue for Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 in terms of value the market will surpass US$1,04,396 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022 report help you?

In summary, our 370-page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 Market, with forecasts and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for five regional markets – See forecasts for the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, South America, Middle East and Africa.

• Prospects for established firms and those seeking to enter the market – including company profiles for 50 of the major companies involved in the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032.


Read the full report: https://www.reportlinker.com/p06368576/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001